Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination
with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.